Navigation Links
Astellas Names Head of Global R&D Operations

DEERFIELD, Ill., June 10 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Peter Carberry, has been hired as the senior vice president and head of global development operations. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform including the data sciences and clinical operations organizations.

"We are pleased that Peter has joined Astellas and we know that he will contribute significantly to the development of innovative products," said Dr. Steven Ryder, president of APGD. "Peter is one of several key hires at APGD that were brought on to strengthen and accelerate our research and development function."

Prior to joining Astellas, Carberry was the vice president of clinical operations, development planning and performance analysis and the office of international development at Genentech. In that role, Carberry developed a global platform for the execution of non-clinical and clinical activities and established many key relationships with company stakeholders. Previously, Carberry was the senior vice president of global clinical operations at Johnson & Johnson Pharmaceutical Research and Development. Dr. Carberry began his industry career with Pharmacia at the Kalamazoo Research site where he held positions of increasing responsibility across the development organization. Carberry earned his M.D. at the University of Nairobi in Kenya and completed his Post Doctoral Fellowship in Clinical Pharmacology at the University of Texas. He earned his M.B.A. at Western Michigan University.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at

SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Adds CNS Therapy Area Leader to Global R&D Team
2. Astellas Hires New Vice President of Compliance
3. Astellas Announces New Vice President of Marketing
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
6. FDA Approves Additional Indication for Astellas MYCAMINE(R)
7. Cardiome And Astellas Announce Regulatory Update
8. Spectrum Names Katherine Maynard Chief Operating Officer
9. Sarnova Names Hank Struik Chief Executive Officer
10. Aptium Oncology Names New Chief Operating Officer
11. National Parkinson Foundation Names New Chief Information Officer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a ... to celebrate their sobriety and show through pictures what a positive difference it ... this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for ... , For 65 years, Brillianteen has been a treasured tradition for ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against ... nation’s roadways has dropped below 10,000 for the first time since 2011. In 2014, ... , According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015  Linden Care, LLC, a retail specialty ... for patients suffering from chronic pain, said today that ... Restraining Order (TRO) enjoining Express Scripts from unilaterally terminating ... --> --> The company ... legal options. --> --> ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology: